Guideline document
This guideline is provided for in-page reading only. Please contact the publishing organization for downloadable copies.
Rhabdomyosarcoma PDQ®
Topic overview
Comprehensive NCI clinical reference for healthcare professionals managing childhood rhabdomyosarcoma, the most common soft tissue sarcoma in children. Covers evidence-based treatment protocols including multimodal therapy with surgery, chemotherapy, and radiation, plus risk stratification and prognosis.
Key Takeaways
- Rhabdomyosarcoma is the most common soft tissue sarcoma in children, arising from primitive mesenchymal cells
- Risk stratification depends on histology (embryonal vs alveolar), primary site, tumor size, nodal status, and metastases
- Multimodal therapy combining surgery, chemotherapy, and radiation achieves 5-year survival >70% in localized disease
- Alveolar subtype with PAX-FOXO1 fusion carries worse prognosis and requires intensified chemotherapy protocols
- Treatment aims to balance cure with minimizing long-term toxicity; organ preservation is prioritized when oncologically safe
Keywords
Hashtags
Full guideline text
Full text not available for this guideline
How to cite: GlobalCastMD. Rhabdomyosarcoma PDQ®. GlobalCastMD Medical Library. https://library.globalcastmd.com/guideline/2385
Comments